Document:

EX-10.5

 Exhibit 10.5 

Quality and Manufacturing Agreement 

by and between 
 CEP Bio-Coat, LLC dba Orchid Detroit 
 and 

SI-BONE, Inc. 

This Quality and Manufacturing Agreement (this “Agreement”), effective April 18, 2016 (“Effective Date”), is by and
between Orchid MPS Holdings, LLC (“Supplier”) with its principal office at 1489 Cedar Street, Holt, MI 48842, and SI-BONE, Inc., a Delaware corporation with its principal office at 3055 Olin
Ave., Suite 2200, San Jose, CA 95128 (“Purchaser”). 
 WHEREAS, the Purchaser develops and designs medical devices and from time
to time may seek to have such devices manufactured for it by the Supplier; and 
 WHEREAS, the Supplier has expertise in the manufacture of
medical devices and components and desires to provide manufacturing services for the Purchaser. 
 NOW, THEREFORE, in consideration of the
mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
  

	1.	 Definitions. Unless otherwise defined in this Agreement, as used herein, the
following defined terms shall have the meanings given them below. 

  

	 	1.1.	 “Affiliate” means any entity which directly or indirectly controls, is controlled by, or is under
common control with the referenced party. For purposes of this Section 1.1, “control,” when used with respect to any entity, means the power to direct or cause the direction of the management and policies of such entity, directly or
indirectly, whether through ownership of voting securities or by contract or otherwise, and the terms and “controlled by” and “under common control” have meanings correlative to the foregoing. 

 

	 	1.2.	 “Bankruptcy Event” means the institution of voluntary or involuntary proceedings by or against a
person or entity in bankruptcy or under any insolvency law, or the appointment of a receiver or custodian for such person or entity, or the institution of proceedings by or against such person or entity for corporate reorganization or the
dissolution of such person or entity, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or an assignment by such person or entity for the benefit of its creditors.

  

	 	1.3.	 “Default” has the meaning given in Section 10.3. 

 

	 	1.4.	 “Forecast” has the meaning given in Section 3.4. 

 

	 	1.5.	 “Intellectual Property” means any inventions, improvements, developments, or innovations (including
all rights to patents, copyrights, trademarks, and trade secrets and know-how inherent therein and appurtenant thereto) and other creative works (whether or not patentable or copyrightable, conceived or made
or reduced to practice), know-how, technical 

  
 [*] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
information, pending patent applications, registrations, divisions and continuations thereof, registered and unregistered copyrights, and all associated goodwill, designs, drawings,
specifications, vendor lists, manufacturing methods and processes, and all other information pertinent to this Agreement, which is proprietary to a party. 

  

	 	1.6.	 “Order” has the meaning given in Section 3.5. 

 

	 	1.7.	 “Process” means the methods and all referenced procedures used in the manufacture of any Product.

  

	 	1.8.	 “Product” means the product or products to be manufactured hereunder pursuant to mutual agreement of
the parties and as described in the Specifications for such Product. 

  

	 	1.9.	 “Product Device Master Record” means the Product Device Master Record for the Product required by the
Regulatory Authorities, as it may be revised and in effect from time to time. 

  

	 	1.10.	 “Purchase Price” has the meaning given in Section 3.1. 

 

	 	1.11.	 “Regulatory Authority” means the Food and Drug Administration of the United States (the
“FDA”) or, any successor agency or, if applicable in the context, the government agency performing the same regulatory functions as the FDA in another country. 

 

	 	1.12.	 “Specifications” means the specifications for the Product as provided in the Product Device Master
Record. 

  

	2.	 Supply Rights. 

 

	 	2.1.	 Manufacture and Supply. Subject to the terms and conditions of this Agreement, the Supplier shall
manufacture the Products for and supply them to the Purchaser. 

  

	 	2.2.	 Third Party Supplier. All Products must be manufactured and assembled solely by the Supplier. Supplier
will not engage any third parties to provide services or goods relating to this Agreement without Purchaser’s prior written approval. If use of a third party supplier is agreed upon by the Purchaser, the Supplier shall have a Quality Agreement,
giving effect to each of the affirmative obligations regarding quality assurance set forth herein, with any third party supplier used for production, packaging, testing, sterilization, processing, or release. Upon the Customer’s request, the
Supplier will provide a copy of the Quality Agreement. 

  

	3.	 Orders, Prices, Terms, Delivery, Forecast and Inventory. 

 

	 	3.1.	 Purchase Price. Purchaser shall pay the amounts set forth on Purchase Orders (as described below), and
specifying in reasonable detail the Product(s) covered thereby, the applicable pricing (“Purchase Price”). Pricing shall be in US dollars. Supplier shall pay all contributions, taxes and premiums payable under federal, state and local laws
measured upon the payroll of employees and agents engaged in the performance of work under this Agreement. Except as otherwise agreed to in writing by the parties, adjustments to the Price shall be made no more than once every twelve
(12) months. The parties will meet annually to review changes in production costs, and Supplier shall share a reasonably detailed analysis of Supplier’s direct and indirect costs incurred in the manufacture of the Products. In connection
with such annual cost review meeting, Supplier may submit a written request for a price increase if is direct costs have increased by more than [*] from its direct costs over the preceding supply year. Purchaser may submit a written request for a
price decrease if Supplier’s direct costs have decreased by more than [*] from its direct costs over the preceding supply year. New prices will be effective immediately upon being agreed to in writing by both parties or at such other time as
may be agreed to in writing by both parties. Pricing may be modified upon any changes to the Specifications of the Products made by Purchaser. 

  
 Page 2 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	3.2.	 Orders, Shipping Terms, and Inconsistencies. All shipments of Products shall be F.O.B. Origin, and shall
be accompanied by a packing slip that describes the Products and states the Order number. Purchaser shall pay all shipping costs. Title to and all risk of loss or damage shall pass to Purchaser upon shipment of the Products from the Supplier to
Purchaser’s designated point of delivery. If there is any conflict or inconsistency between this Agreement and any Purchase Order, Order release, confirmation, acceptance or any similar document, the terms of this Agreement shall govern and
control. 

  

	 	3.3.	 Payment. Supplier shall invoice Purchaser for each Product no earlier than its date of shipment.
Purchaser shall pay the Purchase Price shown on each undisputed invoice within [*] of its receipt of the same. 

  

	 	3.4.	 Forecasts. Purchaser shall provide to the Supplier no later than the fifteenth day of each calendar
quarter, a non-binding (except as otherwise specified herein) rolling estimate by month of the Purchaser’s requirements for orders and deliveries of the Products for [*] period (“Forecast”).
Each Forecast shall update prior Forecasts as well as provide estimates for the time period added to the Forecast over the prior Forecast. 

  

	 	3.5.	 Orders. The Purchaser will submit binding firm purchase orders (the “Order(s)” or
“Purchase Order(s)”) for Products to the Supplier by mail, facsimile, or electronically. Each Order shall contain the following information: (i) a description of the Product by part and revision number; (ii) the quantity of the
Product to be delivered to the Purchaser; (iii) the current applicable Purchase Price for such Products, (iv) the delivery date or shipping schedule; (v) the location to which the Product is to be shipped; and (vi) transportation
instructions. Each Order shall provide an Order number for billing purposes, and may include other instructions and terms as may be appropriate under the circumstances. The lead times for each Product (“Product Specific Lead Times”) shall
be determined by mutual agreement of the parties upon delivery of the Specifications and agreement by the Supplier to supply the applicable Product. 

  

	 	3.6.	 Emergency Deliveries. Notwithstanding Section 3.5, in the event that Purchaser desires to place
Orders for Products requiring delivery within a shorter period than the Product Specific Lead Time(s) (“Emergency Purchase Orders”), Purchaser shall notify Supplier and Supplier shall provide the Purchaser with a commercially reasonable
written estimate of any additional costs (the “Emergency Quote”) that would be incurred to manufacture Products to meet the delivery schedule in an Emergency Purchase Order. Supplier will be obligated to supply such Products in the manner
specified in an Emergency Purchase Order only if the Purchaser agrees in writing to pay the additional costs set forth in the Emergency Quote. Upon Purchaser’s written acceptance of the Emergency Quote, the Supplier agrees to meet such delivery
schedules specified in such Emergency Purchase Orders. 

  

	 	3.7.	 Excess and Obsolete Inventory. If Purchaser cancels or materially changes any Order, Supplier shall make
good faith efforts to mitigate any costs which may be incurred with such Order changes. Notwithstanding the foregoing, should any inventory (including finished goods,
works-in-process, components, or raw materials) be rendered excess or obsolete (as agreed upon by both Purchaser and Supplier) due to (i) the cancellation by
Purchaser of any Orders, or (ii) changes or modifications to Orders, and that cannot reasonably and without extra cost to the Supplier be utilized on other Supplier products or returned to its suppliers, or such damages otherwise mitigated, the
impact of such changes will be the financial responsibility of the Purchaser, at the Supplier’s documented actual costs (including, but not limited to, restocking charges paid by the Supplier to its suppliers, labor, and component costs).
Notwithstanding the foregoing, Supplier will accept all financial responsibility for inventory purchased in excess of the then-current Forecast 

  
 Page 3 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	4.	 Quality. 

 

	 	4.1.	 Manufacturing Processes and Approvals. Supplier will manufacture Products that fully conform with:
(i) Product Specifications supplied by Purchaser, (ii) applicable regulations relating to 21 CFR Part 820 Quality System Regulations, Good Manufacturing Practices, including device and lot history records, (iii) quality system
requirements of ISO 13485 and MDD 93/42/EEC, and (iv) in accordance with a risk management system conforming to the requirements of ISO 14971. 

  

	 	4.2.	 Changes by Supplier: Manufacturing. Supplier shall make no change to the Specifications, Process,
Product tooling design, processing conditions, materials or manufacturing location without Purchaser’s prior written approval. Supplier shall provide a written request for any such change. Such request must include a description of the specific
proposed change, the reason for the proposed change, the perceived benefit that will be derived from the proposed change, the perceived potential loss that may arise from failure to make the proposed change, and the anticipated lead time that will
be necessary to make the proposed change. For accepted changes, the Supplier and Purchaser will work together to develop an implementation plan. 

  

	 	4.3.	 Changes by Supplier: Deviations. Supplier shall provide a written request for any deviation from a
document, specification, drawing, etc. Such request must explain the specific proposed deviation, the reason for the proposed deviation, and the period (time, lots, etc.) the proposed deviation is to be in effect. Supplier shall not proceed with a
deviation without Purchaser’s prior written approval. 

  

	 	4.4.	 Disposition of Non-Conforming Material. The Supplier shall
identify, segregate and investigate all nonconforming material. The Supplier may make scrap dispositions without Purchaser’s prior written approval. Suppler shall not make concession (“use as is”) or rework dispositions without
Purchaser’s prior written approval. Supplier shall provide a written request for any concession (“use as is”) or rework disposition. Such request must include the inspection or test conducted, the actual results, and if applicable,
the proposed disposition or repair. In the event a disposition is approved, Supplier shall update the production-monitoring portion of the ISO 14971 Risk Management File to include information on the nonconformity. If the Supplier performs rework, a
written history of all rework and/or corrective actions shall accompany the Product shipped to Purchaser. 

  

	 	4.5.	 Corrective Action. Supplier shall initiate corrective action for all detected nonconforming material
regardless of disposition. Corrective action shall include (1) Investigation (including impact to product already released) and determination of root cause, (2) Proposed corrective action to prevent recurrence, (3) Implementation of
corrective actions, and (4) Verification of the effectiveness of the corrective action. The Supplier shall report the results of the corrective action to the Purchaser within fifteen (15) working days of initiation. The Supplier shall keep
records of these activities and make them available to the Purchaser upon request. 

  

	 	4.6.	 Device History Record. The Supplier and Purchaser will maintain the following portions of the Device
History Record required by 21 CFR §820.181. Supplier shall keep records of these activities and make them available to the Purchaser within one business day of request. 

 

	 	a.	 Device specifications (Purchaser) 

 

	 	b.	 Production process specifications (Supplier) 

 

	 	c.	 Quality assurance procedures and specifications (Supplier) 

 

	 	d.	 Labeling specifications (Purchaser) 

 

	 	e.	 Packaging specifications (Supplier) 

  
 Page 4 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	f.	 Maintenance procedures and methods records (Supplier) 

 

	 	4.7.	 Labeling Operations. Supplier shall control all labeling operations to prevent labeling errors. Supplier
shall record all labeling activities on the Device/Lot History Record. 

  

	 	4.8.	 Packaging Operations. Supplier shall pack and package Product using best practices to protect Product
from deterioration or damage during processing, storage, handling, and shipment. Supplier shall record all packaging activities on the Device/Lot History Record. 

 

	 	4.9.	 Environmental Controls. If environmental conditions could reasonably be expected to have an adverse
effect on product quality, the Supplier shall establish and maintain procedures, including maintenance, adjustment, and inspection to adequately control these environmental conditions. The Supplier shall keep records of these activities and make
them available to the Purchaser upon request. 

  

	 	4.10.	 Personnel. If contact between personnel and the product could reasonably be expected to have an adverse
effect on product quality, the Supplier shall establish and maintain requirements for the health, cleanliness, personal practices, and clothing of personnel to adequately control this contact. The Supplier shall keep records of these activities and
make them available to the Purchaser upon request. 

  

	 	4.11.	 Equipment. The Supplier shall ensure that all equipment used in the manufacturing process for product is
appropriately designed, constructed, placed, and installed. The Supplier shall establish and maintain schedules for the calibration, adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met. The
Supplier shall keep records of these activities and make them available to the Purchaser upon request. 

  

	 	4.12.	 Inspection, Measuring, and Test Equipment. The Supplier shall ensure that all inspection, measuring, and
test equipment (IM&TE) used in the manufacturing process for product is suitable for its intended purposes and is capable of producing valid results. Suitability includes limits for accuracy and precision. The Supplier shall establish and
maintain schedules for the calibration, adjustment, cleaning, and other maintenance of equipment to ensure that manufacturing specifications are met. Calibration standards used for IM&TE shall be traceable to national or international standards.
The Supplier shall keep records of these activities and make them available to the Purchaser upon request. 

  

	 	4.13.	 Process Validation. If the output of a Supplier’s process is not fully verified by subsequent
inspection or test, the Supplier shall validate the process with a high degree of assurance, [*]. 

 The validation
process shall create a validation protocol (describing the planned activities) and a validation report (documenting the outcome of the planned activities). All validated process changes shall be similarly validated prior to use. The Supplier shall
keep records of these activities and make them available to the Purchaser upon request. When the Supplier ships products produced using a validated process, the Supplier shall include process documentation showing the date the process was operated,
the name of the operator, the identity of major equipment used, the identity and calibration date of the IM&TE used in the process, and the setting of each input process parameter. 

 

	 	4.14.	 Facility Inspections by Purchaser. Purchaser shall have the right, upon reasonable advance written
notice and during regular business hours, to inspect the facilities being used by the Supplier for production and storage of the Products. If any such inspection reveals that the facilities do not satisfy Purchaser’s requirements, then
Purchaser shall provide written notification, which notice shall contain in reasonable detail the identified deficiencies and, if practicable, remedial efforts the Supplier should undertake. Supplier shall remedy all

  
 Page 5 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
identified deficiencies within [*] days following Purchaser’s written notification. In the event the deficiencies are not remedied within such [*] day period, Supplier shall be in material
breach of this Agreement and Purchaser shall have the right to immediately terminate this Agreement. 

  

	 	4.15.	 Facility Inspections by Regulatory Authorities. Supplier shall notify Purchaser within 24 hours of any
communication, correspondence, inquiry, inspection, audit or investigation by any regulatory authority or notified body in relation to the services provided under this Agreement or Purchaser’s Products. Supplier shall consult and cooperate with
Purchaser in responding to the regulatory authority, which shall include providing Purchaser access to all related documents and other information received from any regulatory authority or notified body. If requested, the Supplier will allow
regulatory authorities and/or the Purchaser to inspect Product, storage locations, inventory and records. In the event a regulatory authority requests an inspection, Supplier will immediately contact Purchaser and inform the Purchaser of the
inspection. In any event, Supplier shall neither make any commitments nor provide any undertakings, which, in either case, relate directly to the Products, to any regulatory authority or notified body without the prior written approval of Purchaser.
Supplier’s failure to comply with this Article “Inspection by Regulatory Authorities” shall be a material breach of this Agreement and Purchaser shall have the right to immediately terminate this Agreement. 

 

	 	4.16.	 Quality System Audits. Purchaser shall have the right, upon reasonable advance written notice and during
regular business hours, to perform audits of Supplier’s systems, documentation, and other requirements related to this Agreement. Audits shall be conducted at mutually agreed dates and times. 

 

	 	4.17.	 Records. Supplier will maintain records with respect to the manufacture of the Products for [*] after
the last Product has been manufactured, at which time such records will be returned to Purchaser for maintenance or destruction. 

  

	 	4.18.	 Product Complaints. With respect to Product complaints, Purchaser shall be considered the
“manufacturer” for regulatory purposes and is responsible for filing all required Medical Device Reports. If Purchaser reasonably believes that a complaint relates to a breach by the Supplier of the warranty contained in Section 5.1,
Purchaser will forward the complaint to the Supplier and Supplier shall be responsible to remedy the noncompliance as provided in Section 5.2. If the Supplier receives a complaint related to the product, or any similar product, the Supplier
provides to the Purchaser, the Supplier shall promptly notify the Purchaser. Purchaser will enter the complaint into the Purchaser’s Complaint Management System (21 CFR §820.198) and review and evaluate the complaint to determine whether
an investigation is necessary. The Supplier shall provide assistance in a complaint investigation as requested by the Purchaser. 

  

	 	4.19.	 Corrections and Removals. If the Supplier files a Corrections or Removals for the product, or any
similar product that the Supplier provides to the Purchaser, the Supplier shall promptly notify the Purchaser. The Purchaser is responsible for managing corrections or removals of SI-BONE product.

  

	 	4.20.	 Sterilization Services. Sterilization will be provided and managed by Supplier. Supplier and Purchaser
will jointly review the sterilization validation protocol and report, which will include the results of sterilization validation and revalidation. Supplier will provide all sterilization documentation to Purchase upon request. 

 

	 	4.21.	 Manufacturing Process Documentation. The supplier shall provide the following documentation with each
product lot shipped to the Purchaser: 

  

	 	a.	 Sterilization Certificate 

  
 Page 6 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	b.	 Package Labeling Documentation 

 

	 	c.	 Job Order Pick List 

  

	 	d.	 Line Clearance Forms 

 

	 	e.	 Supplier Certificate of Conformance 

 

	 	f.	 Material Certificates 

 

	 	g.	 Supplier Inspection Sheets 

 

	 	h.	 Copy of any related Non-Conforming Material Reports

  

	 	4.22.	 Storage and Shipment. 

 

	 	4.22.1.	 Storage. The Supplier shall establish and maintain procedures to control storage areas and stock rooms to
prevent mix-ups, damage, deterioration, contamination, or other adverse effects. The Supplier shall ensure that all products are stored to facilitate proper stock rotation and that product is retrieved from
stock using First In, First Out (FIFO) methodology. 

  

	 	4.22.2.	 Shipment. The Supplier shall ship products to the Purchaser using shipping methods that will prevent the damage
or deterioration of the product. 

  

	5.	 Product Warranty and Limited Remedies.  

 

	 	5.1.	 Warranty. Supplier represents and warrants that the Products furnished under this Agreement shall be
free from all defects in workmanship and materials and shall conform to the Specifications for a period of [*] after delivery to Purchaser. 

  

	 	5.2.	 Remedies. If Supplier fails to meet the warranty stated in Section 5.1 with respect to any Product,
the Supplier shall, at the Purchaser’s option, either (i) repair or replace such Product at the Supplier’s own expense, and ship such repaired or replacement Product to either the Purchaser or the applicable customer at the
Supplier’s own expense, or (ii) credit to the Purchaser the Purchase Price for the non-conforming Product. If reasonably possible, all defective Products covered by the foregoing warranty shall be
shipped to the Supplier at Supplier’s expense for such repair or replacement. 

  

	 	5.3.	 Exclusions from Warranty. The warranty set forth in Section 5.1 above does not include Products
that have defects or failures resulting from Purchaser’s design of Products as set forth in the Specifications, including, but not limited to, design functionality failures, Specification inadequacies, failures relating to the functioning of
Products in the manner for the intended purpose or failures resulting from unauthorized modification of the Products. To the extent that all Product designs have been provided by Purchaser to Supplier, Purchaser bears all design responsibility for
the Product. 

  

	 	5.4.	 Disputes. If the Supplier disagrees with a claim that a Product does not conform to the warranty
provided in Section 5.1, then the parties agree to submit the disputed Product to a mutually agreed-upon independent party to test the Product to determine whether it conforms. The cost of such testing shall be borne by the party against whom
the testing party finds. 

  

	 	5.5.	 Limitation of Liability. EXCEPT FOR THE PARTIES’ INDEMNIFICATION OBLIGATIONS UNDER SECTION 6 AND
OBLIGATIONS OF CONFIDENTIALITY UNDER SECTION 9, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY PUNITIVE, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, PERSONAL INJURY AND PROPERTY DAMAGE, EQUIPMENT DAMAGE, LOSS OF
PROFITS OR REVENUES OR BUSINESS, COST OF CAPITAL, COST OF PURCHASE, COST OF RECALL, OR COST OF THIRD PARTY REPLACEMENT GOODS. IN NO EVENT SHALL PURCHASER’S TOTAL AGGREGATE LIABILITY UNDER THIS AGREEMENT, WHETHER BASED UPON CONTRACT, TORT, OR
OTHERWISE EXCEED [*]. 

  
 Page 7 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	6.	 Indemnification. 

 

	 	6.1.	 By Supplier. Supplier agrees to indemnify and hold Purchaser, its affiliates, officers, directors,
agents and employees (“Purchaser Indemnitees”) harmless from and against all actions, liabilities, losses, damages, claims and demands whatsoever, including, but not limited to, attorney fees and other expenses (“Claims”) that
are brought or threatened against the Purchaser Indemnitees and related to Supplier’s or Supplier Indemnitee’s: (a) breach of this Agreement; (b) violation of applicable laws and regulations; (c) breach of representations
and warranties; (d) any claim of Intellectual Property infringement brought by third parties arising from Supplier’s manufacturing processes or Supplier’s services provided hereunder, provided such infringement is not a direct result
of specifications or instructions provided by Purchaser; or (e) negligence, recklessness or willful misconduct. The duty to indemnify will not apply to the extent that any Claim arises from the negligence, recklessness, or willful misconduct of
a Purchaser Indemnitee. 

  

	 	6.2.	 By Purchaser. Purchaser agrees to indemnify and hold Supplier, its affiliates, officers, directors,
agents and employees (“Supplier Indemnitees”) harmless from and against all Claims that are brought or threatened against the Supplier Indemnitees and related to: (a) Purchaser’s breach of this Agreement;
(b) Purchaser’s violation of applicable laws and regulations; (c) defects or alleged defects in the design of the Products, provided such design defects are a result of specifications or instructions provided by Purchaser;
(d) infringement upon the Intellectual Property rights of third parties, provided such infringement is a direct result of specifications or instructions provided by Purchaser; or (e) Purchaser’s negligence, recklessness or willful
misconduct. The duty to indemnify will not apply to the extent that any Claim arises from the negligence, recklessness, or willful misconduct of a Supplier Indemnitee. 

 

	 	6.3.	 General. The party claiming indemnity (the “Indemnified Party”) shall provide the party from
whom indemnity is being sought (the “Indemnifying Party”) with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the claim for which indemnity is being sought. The Indemnifying Party shall
have the right to assume sole control over the defense of such claim and conduct the defense of the claim with counsel of its choice. The Indemnifying Party shall not settle any claim without the prior written consent of the Indemnified Party, not
to be unreasonably withheld, unless the settlement involves only the payment of money. 

  

	 	6.4.	 Insurance. Each party agrees to procure and maintain in full force and effect during the term of
this Agreement collectible insurance policies in connection with the manufacture, supply and sale of Products pursuant to this Agreement and provide: (i) for commercial general liability coverage in the amount of [*] per occurrence and [*] in
the aggregate, excluding Products and Completed Operations coverage and written on either an occurrence or a claims made basis; and (ii) Products and Completed Operations coverage in the amount of [*] per occurrence and [*] in the aggregate and
written on a claims-made basis. Each party shall endeavor to provide the other party with thirty (30) days written notice of cancellation or ten (10) days’ notice for non-payment of premium or
termination of any such policy. Upon either party’s request, the other party shall provide to the requesting party a certificate of insurance coverage. 

  

	7.	 License, Ownership; Tooling. 

 

	 	7.1.	 Limited License Grant. Purchaser grants Supplier a
non-exclusive, nontransferable, worldwide license, without the right to sublicense, to use all designs, materials, information, 

  
 Page 8 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
know-how and documentation, including the Specifications, provided by Purchaser to Supplier, solely in connection with manufacturing the Products hereunder
for supply of such Products to Purchaser or parties designated by Purchaser. This license shall not include the right to modify, make derivative works of or improvements to the Products and shall terminated upon the termination or expiration of this
Agreement. 

  

	 	7.2.	 Ownership of Intellectual Property. All Intellectual Property of Purchaser existing on or prior to the
execution of this Agreement shall be and remain the property of Purchaser, and Supplier shall not acquire any rights therein, except as expressly provided in Section 7.1 of this Agreement or in the License Agreement. Purchaser shall own, and
Supplier hereby assigns to Purchaser, all worldwide right, title and interest in and to the Products, all Intellectual Property conceived or reduced to practice by Supplier, its employees or agents in the course of performing Supplier’s duties
hereunder, or as a result of access to Purchaser’s Intellectual Property, and any modification, derivative work of or improvement to the Products and/or Purchaser’s Intellectual Property. All rights not expressly granted herein are
reserved. Supplier shall execute all papers, including patent applications, invention assignments and copyright assignments, and otherwise shall assist Purchaser as reasonably required to perfect in the Purchaser the rights, title and other
interests held by Purchaser under this Agreement. Purchaser shall pay for reasonable costs related to such assistance. If Purchaser is unable for any reason, after reasonable effort, to secure Supplier’s signature on any document needed in
connection with the actions specified above, Supplier hereby irrevocably designates and appoints Purchaser and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest, to act for and
in its behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by Supplier. Notwithstanding anything
contained in this Agreement to the contrary, 

  

	 	7.3.	 Tooling and Equipment. All tooling and equipment used by the Supplier to manufacture the Products shall
be the property of the Supplier, unless any such tooling and equipment is specifically provided by the Purchaser or purchased by the Purchaser from the Supplier over and above the Purchase Price for the Products. The agreement of the parties
concerning any tooling and equipment so provided or purchased by the Purchaser shall be set forth in a separate document that is agreeable to both parties. 

  

	8.	 Confidentiality; Publicity. 

 

	 	8.1.	 Confidentiality. The Purchaser and the Supplier will have access to each other’s Confidential
Information (as defined herein). “Confidential Information” means any trade secret, other information viewed by the party disclosing it (the “Disclosing Party”) as confidential and/or proprietary, and any and all information or
proprietary materials (in every form and media) not generally known in the relevant trade or industry made available by either party to the party receiving such information (in such case, the “Receiving Party”) in connection with the
efforts contemplated hereunder and which the Disclosing Party designates as confidential or may reasonably be understood as confidential, including, but not limited to (i) all Intellectual Property of either Party; (ii) existing or
contemplated products, services, designs, inventions, technology, processes, technical data, engineering, techniques, methodologies and concepts and any information related thereto; and (iii) information relating to business plans, sales,
consultants, employees, or marketing methods and customer lists or requirements. The Receiving Party will maintain the information in confidence using the same standard of care it uses to maintain its own Confidential Information in confidence, but
in any case, no less than reasonable commercial diligence, and will not use such information for itself or others except as provided in this Agreement. Such obligation of confidentiality and non-use shall not
apply to information which (a) is known to the Receiving Party prior to the disclosure as demonstrated by documentary evidence, (b) is publicly known as of the date of the

  
 Page 9 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
disclosure, (c) becomes publicly known after the date of disclosure through no fault of the Receiving Party, (d) is received by the Receiving Party from a third party who has, to the
Receiving Party’s knowledge, no obligation of confidentiality to the Disclosing Party, or (v) is developed independently by the Receiving Party without reference to the Disclosing Party’s Confidential Information as demonstrated by
documentary evidence. Such obligation of confidentiality and non-use shall survive any expiration or termination of this Agreement. The restrictions on disclosure contained in this Section 9.1 shall not
apply to any information which is required to be disclosed by a valid court rule or governmental law or regulation, provided that the Receiving Party gives the Disclosing Party prompt notice of any such requirement and cooperates with the Disclosing
Party, at the Disclosing Party’s expense, in attempting to limit such disclosure and obtain confidential treatment thereof. 

  

	 	8.2.	 Publicity. Neither party will originate any publicity, news release, or other public announcement,
written or oral, whether to the public, press or otherwise, relating to this Agreement or any amendment hereto or to performance hereunder or the existence of an arrangement between the parties, without the prior written approval of the other party,
such approval not to be unreasonably withheld. 

  

	 	8.3.	 Use of Names in Promotions. Neither party shall use the name of the other for advertising or promotional
claims without the prior written consent of the other party. 

  

	 	8.4.	 Damages Inadequate. The parties acknowledge that monetary damages may be an inadequate remedy for any
breach by a party of its obligations under Section 9.1 and that the non-breaching party shall be entitled to seek injunctive relief and specific performance to enforce the breaching party’s
obligations, in addition to any other remedies the non-breaching party may be entitled to at law. 

  

	9.	 Term and Termination. 

 

	 	10.1.	 Term. Unless sooner terminated as provided in Section 10.2 below or in Section 12.6, this
Agreement shall have a term commencing on the Effective Date and expiring the date three (3) years thereafter. 

  

	 	10.2.	 Termination. This Agreement may be terminated: 

 

	 	(i)	 upon written notice by either party to the other party, if the other party is in Default (as defined in
Section 10.3 below); 

  

	 	(ii)	 By written notice from the Purchaser to the Supplier in accordance with Section 4; or

  

	 	(iii)	 By either party upon twelve (12) months written notice to the other party. 

 

	 	10.3.	 Default. A party shall be in “Default” (i) if such party becomes the subject of a Bankruptcy
Event; (ii) with respect to Purchaser, if Purchaser fails to make full payment of the Purchase Price when due and such failure continues for [*] after notification of non-payment by Supplier; or
(iii) if such party breaches any other material provision of this Agreement and fails to remedy such default within [*] after receipt of written notice thereof, which notice shall state, with particularity, the grounds for such claimed default.

  

	 	10.4.	 Effect of Termination. Upon any expiration or termination of this Agreement, each party shall either
return to the other or destroy, upon the other party’s request, all Confidential Information, Intellectual Property and any other proprietary materials of such requesting party. The provisions of Sections 4.6, 4.11, 4.17, 4.18, 5, 6, 7, 8, 9,
10.4, 11, and 12 shall survive any termination or expiration of this Agreement. 

  
 Page 10 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	10.	 Risk Management. 

 

	 	11.1.	 Contingency Plan. Supplier shall create and maintain a contingency plan to prevent an interruption of
Product supply in the event that normal business is disrupted (“Contingency Plan”), which shall be approved in advance in writing by Purchaser. Changes to the Contingency Plan may not be made without Purchaser’s prior written
approval. Supplier will review the Contingency Plan on a semi-annual basis to ensure the necessary components remain in place. The Contingency Plan shall contain adequate provisions for each of the following: 

 

	 	a.	 Off-site storage for tools and tool drawings; 

 

	 	b.	 Raw material acquisition; 

 

	 	c.	 Back-up site(s) for manufacturing capability; and

  

	 	d.	 Assurance that, given an interruption in the normal business process, Products could be produced within [*] of
such interruption. 

  

	11.	 Miscellaneous. 

 

	 	11.1.	 Independent Contractor Status. The relationship between the Supplier and the Purchaser is that of
independent contractors, and nothing contained herein shall be deemed to create a relationship of employer and employee, principal and agent, partners, or otherwise. Neither party shall have any authority to obligate the other in any respect nor
hold itself out as having any such authority. All personnel of the Supplier shall be solely employees of the Supplier and shall not represent themselves as employees of the Purchaser, and all personnel of the Purchaser shall be solely employees of
the Purchaser and shall not represent themselves as employees of the Supplier. 

  

	 	11.2.	 Assignment. Neither party may assign, delegate or subcontract its obligations without the other
party’s prior express written consent. Notwithstanding the foregoing, either party shall be permitted to assign all or part of this Agreement to a purchaser of all of, or the applicable portion of, such Party’s business (whether through
asset sale, merger, consolidation, reorganization or other form of transaction) with written notice to the other party, except that Supplier may not assign this Agreement to any party that competes with Purchaser. 

 

	 	11.3.	 Entire Agreement; Amendments. This Agreement is the full, complete, and exclusive agreement between the
parties and supersedes and cancels any and all previous or contemporaneous agreements of whatever nature, whether written or oral, between them with respect to the matters covered herein. This Agreement may only be modified or amended in a writing
signed by both parties. 

  

	 	11.4.	 Severability. In the event that any provision of this Agreement would be held in any jurisdiction to be
invalid, prohibited or unenforceable for any reason, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any
other jurisdiction. Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without
invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction. 

  

	 	11.5.	 Remedies. Unless otherwise expressly provided, all remedies hereunder are cumulative, are in addition to
any other remedies provided for by law and may, to the extent permitted by law, be exercised concurrently or separately, and the exercise of any one remedy shall not be deemed to be an election of such remedy or to preclude the exercise of any other
remedy. 

  
 Page 11 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	11.6.	 Force Majeure. The obligations of the Supplier and the Purchaser hereunder (except for the
Purchaser’s obligations to make payment in full for Products) shall be subject to any delays or non-performance caused in whole or part by any contingency or event beyond either party’s reasonable
control, including, without limitation, any act of God; acts of any government or any agency or subdivision thereof; fire; strikes; war; machinery breakage; failure of a communications or internet provider; transportation delays; shortage of or
inability to secure labor, fuel, energy, materials or supplies at reasonable prices or from regular sources; riots or acts of a public enemy; terrorist acts; and any existing or future laws or regulations with which Supplier, in its judgment and
discretion, deems it advisable to comply as its legal duty. The party which is not performing its obligations under this Agreement as a result of an event of force majeure shall use diligent efforts to resume compliance with this Agreement as soon
as possible. Should the event of force majeure continue unabated for a period of sixty (60) days or more, the party who’s performance has not been delayed or prevented may terminate this Agreement upon notice to the other party.

  

	 	11.7.	 Notices. Any notice, request, consent or communication (collectively, a “Notice”) under this
Agreement shall be effective if it is in writing and (i) personally delivered, (ii) sent by certified or registered mail, postage prepaid, return receipt requested, (iii) sent by an internationally recognized overnight delivery
service, with delivery confirmed, or (iv) telexed or telecopied, with receipt confirmed, addressed as set forth in this Section or to such address as shall be furnished by either party hereto to the other party hereto. A Notice shall be deemed
to have been given as of (a) the date when personally delivered, (b) when received if delivered by the United States Postal Service, certified or registered mail, properly addressed, return receipt requested, postage prepaid, or by
overnight delivery service, or (c) immediately, upon confirmation of receipt of the telex or telecopy, as the case may be. All Notices shall specifically state: the provision (or provisions) of this Agreement with respect to which such Notice
is given and shall be addressed as follows: 

  

					
		 	If to the Supplier:	 	If to the Purchaser:
			
		 	Orchid MPS Holdings, LLC	 	SI-BONE, Inc.
		 	1489 Cedar St.	 	3055 Olin Ave.
		 	Holt, MI 48842	 	Suite 2200
		 	ATTN: VP Sales	 	San Jose, CA 95128
		 		 	ATTN: CFO

  

	 	11.8.	 Permits and Compliance. Supplier agrees to procure all necessary permits or licenses and abide by all
applicable laws, regulations and ordinances of the United States and of the state, territory and political subdivision in which the work under this Agreement is performed. Supplier hereby represents and warrants that it and its personnel:
(i) are not currently excluded, debarred, or otherwise ineligible to participate in federal health care programs as defined in 42 U.S.C. § 1320a-7b(f) (the “Federal Health Care Programs”);
(ii) are not convicted of a criminal offense related to providing health care items or services but have not yet been excluded, debarred, or otherwise declared ineligible to participate in the Federal Health Care Programs, and (iii) are not
under investigation or otherwise aware of any circumstances that may result in being excluded, debarred, or otherwise declared to participate in Federal Health Care Programs 

 

	 	11.9.	 Governing Law. This Agreement will be governed by and constructed in accordance with the laws of
California without regard to the conflicts of the law principles thereof. Any dispute between the Parties in relation to or in connection with this Agreement (including those relevant to the validity, construction, execution and termination of the
same) shall be submitted to the exclusive jurisdiction of courts located in San Jose, Santa Clara County, California. 

  
 Page 12 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	11.10.	 Waivers. The failure of either party to assert a right hereunder or to insist upon compliance with any
term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 

 

	 	11.11.	 Counterparts. This Agreement may be executed in any number of counterparts, and execution by each of the
parties of any one of such counterparts will constitute due execution of this Agreement. Each such counterpart hereof shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement.

  

	 	11.12.	 Headings. The article and section headings contained in this Agreement are for reference purposes only
and shall not affect in any way the meaning or interpretation of this Agreement. 

 [REMAINDER OF THE PAGE INTENTIONALLY
LEFT BLANK] 

  
 Page 13 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth
beneath such person’s name. 
  

									
	 SI-BONE, INC.
	 		 	 ORCHID MPS HOLDINGS, LLC

			
	 /s/ Jeffrey W. Dunn
	 		 	 /s/ Matthew K. Burba

	(Signature)	 		 	(Signature)
			
	Jeffrey W. Dunn	 		 	Matthew K. Burba
	(Print Name)	 		 	(Print Name)
			
	President, CEO	 		 	EVP, Operations
	(Title)	 		 	(Title)
					
	Date	 	April 20, 2016	 		 	Date	 	4/18/2016                                    
    

  
 Page 14 of
14 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Addendum No. 1 to 

Quality and Manufacturing Agreement by and between 

Orchid MPS Holdings, LLC and SI-BONE, Inc. 

This Addendum No. 1 to Quality and Manufacturing Agreement (“Addendum
No. 1”) evidences agreements between Orchid MPS Holdings, LLC together with its subsidiaries and affiliates on the one hand (“Supplier”) and
SI-BONE, Inc. and its subsidiaries and affiliates on the other hand (“Purchaser”) and modifies and supplements that certain Quality and Manufacturing Agreement by and between the
parties with an effective date of April 18, 2016 (the “Original Agreement”, and together with this Addendum No. 1, the “Agreement”). This Addendum No. 1 is intended to, among other
things, allow Supplier to hold a specified level of inventory to better support Purchaser’s business. Capitalized terms used and not defined in this Addendum No. 1 shall have the meaning given them in the Original Agreement. 

I.    Interpretation. Should any conflict exist between this Addendum No. 1 and the
Original Agreement, the terms of this Addendum No. 1 will control. 
  

	 	II.	 Supplier agrees to: 

 

	 	1)	 Hold the equivalent of [*] of machined implants and [*] of finished goods, in each case based on the then
current Forecast. For purposes hereof, “machined implants” shall mean implants ready for TPS-coating and “finished goods” shall mean implants coated, packaged, sterilized and ready for
shipment. Supplier will use [*] of the then current Forecast to make inventory determinations where [*] of finished goods inventory is required hereby. The inventory and lead time requirements set forth in this Addendum No. 1 shall apply only
to items set forth on Schedule A. 

  

	 	2)	 Maintain a lead time not to exceed [*] for finished goods. 

 

	 	3)	 Hold pricing per Schedule A to the Amendment for at least one year from the date of this Addendum No. 1.
Thereafter, price adjustments shall be subject to the mechanism set forth in Section 3.1 of the Original Agreement. 

  

	 	4)	 Keep purchaser informed of any significant changes in its business which could reasonably be foreseen to impact
Supplier’s inventory, lead time, volume limitations or any other aspect of its performance under the Original Agreement or this Addendum No. 1. 

  

	 	5)	 Not to assess any lot charges for one document change each [*]; thereafter, Supplier shall charge Purchaser
only at its reasonable and customary hourly rates for engineering and other administrative time necessary to effectuate documentation changes. 

  

	 	6)	 Participate in [*] Kanban review meetings to discuss: 

 

	 	a.	 Adding parts to the Original Agreement, provided there shall be no obligation on the part of Supplier to accept
such additional parts; 

  

	 	b.	 Removing parts from the Original Agreement; and 

 

	 	c.	 Changing the levels held in inventory for various part numbers. 

 

	 	III.	 Purchaser agrees to: 

 

	 	1)	 Provide a rolling [*] Forecast by part number and month; Purchaser shall make good faith efforts to provide
such Forecast with [*] detail. 

  

	 	2)	 Provide a blanket purchase order for the [*] Forecast no less than [*] prior to the first required delivery
date. 

  

	 	3)	 Release against such blanket purchase order (“Orders” as described in the Original Agreement) shall
be provided at least [*]. Such releases shall be in multiples of the bin size set forth on Schedule A to this Addendum No. 1. 

  
 1. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	4)	 Provide releases against the then current blanket order for any parts that remain in Supplier’s Detroit
inventory of finished goods for more than [*]; provided, however, that Purchaser shall have no obligation to purchase in excess of [*] worth of inventory based on the Forecast at the time of its original procurement by Supplier.

  

	 	5)	 Purchase any inventory throughout Supplier’s supply chain obsoleted by a revision change or obsoleting of
a part, including packaging materials, at material cost (including Supplier’s standard labor rates) unless assembly processing has been completed. 

  

	 	6)	 Participate in [*] Kanban review meetings to discuss: 

 

	 	a.	 Adding parts to the Original Agreement, provided Purchaser shall have no obligation to add parts to the
Original Agreement; 

  

	 	b.	 Removing parts from the Original Agreement; and 

 

	 	c.	 Changing the levels held in inventory for various part numbers. 

 

	 	IV.	 Miscellaneous. 

 

	 	1)	 Ratification. The parties take this opportunity to ratify the Original Agreement and confirm all of
their respective obligations set forth therein, including the representations and warranties made to one another. 

  

	 	2)	 Severability. If any provision of the Original Agreement will be declared invalid, illegal or
unenforceable, such provision will be severed and all remaining provisions will continue in full force and effect. 

  

	 	3)	 Entire Agreement. The Original Agreement, including this Addendum No. 1, is the full, complete, and
exclusive agreement between the parties and supersedes and cancels any and all previous or contemporaneous agreements of whatever nature, whether written or oral, between Supplier and Purchaser and their respective subsidiaries and affiliates with
respect to its subject matter. The Agreement may only be modified or amended in a writing signed by both parties. Subject headings are for convenience of reference only and will in no way affect interpretation of the Agreement.

  

	 	4)	 Counterparts. This Addendum No. 1 may be executed in separate counterparts, and by facsimile, each
of which will be deemed an original, and when executed separately or together, will constitute a single original instrument, effective in the same manner as if the parties had executed one and the same instrument. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 2. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the parties have executed this Addendum No. 1 as of the date
set forth beneath such person’s name. 
  

									
	PURCHASER:	 		 	SUPPLIER:
			
	SI-BONE, Inc.	 		 	Orchid MPS Holdings, LLC
					
	By:	 	 /s/ Laura Francis
	 		 	By:	 	 /s/ Patrick Davidson

	Name:	 	Laura Francis	 		 	Name:	 	Patrick Davidson
					
	Title:	 	CFO	 		 	Title:	 	General Manager
			
	Dated: 3/1/2017	 		 	Dated: 3/1/2017

  
 3. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule A to Addendum No. 1 

to 
 Quality and
Manufacturing Agreement by and between Orchid MPS Holdings, LLC and SI-BONE, Inc. 
  

									
	 Part Number
	  	 Price
	  	 Bin Size
	  	 Weeks

Inventory
 (finished

goods)
	  	 Weeks

Inventory

(machined)

	 [*]
	  	[*]	  	[*]	  	[*]	  	[*]

  
 4. 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.6

 Exhibit 10.6 

MANUFACTURING, QUALITY AND SUPPLY AGREEMENT 

THIS MANUFACTURING, QUALITY AND SUPPLY AGREEMENT (“Agreement”) is entered into as of
January 31, 2017 (the “Effective Date”), between SI-BONE, INC., a Delaware corporation having an address of 3055 Olin Ave., Ste.
2200, San Jose, CA 95128 (including its Affiliates, “SI-BONE”) and rms COMPANY a Minnesota corporation having an address of 8600 Evergreen Blvd., Coon Rapids, MN 55433
(“Supplier”). 
 RECITALS 

WHEREAS, SI-BONE desires to engage the services of Supplier to perform the Manufacture of the
Products (as those terms are defined below) for use and sale by SI-BONE, on the terms and conditions set forth below, and 

WHEREAS, Supplier desires to perform Services for SI-BONE on the terms and conditions set forth
below. 
 AGREEMENT 

The parties, intending to be legally bound, agree as follows: 
  

	1.	 AGREEMENT TO SUPPLY; FORECASTS. 

 

	 	1.1	 Agreement to Supply. Except as provided in this Agreement, during the Term Supplier shall
supply on a non-exclusive basis and pursuant to this Agreement Product to SI-BONE to be sold, distributed or used otherwise as provided by
SI-BONE. The parties acknowledge and agree that the accessories used in connection with the Product may be purchased by SI-BONE from Supplier or a third-party vendor or
manufactured directly by, or otherwise obtained through, SI-BONE. 

  

	 	1.2	 Forecasts. Within ten days after the Effective Date, SI-BONE shall deliver to Supplier a forecast of its requirements for the Product for each of the calendar quarters ending June 30, 20XX, September 30, 20XX, December 31, 20XX, and March 31, 20XX
(with the period ending March 31, 2017 including the period starting with the Effective Date) (the “Forecast”). No later than ten days following the end of each [*] during the Term, SI-BONE shall update the Forecast in writing by providing to Supplier an updated Forecast for the following [*] (or such fewer number of [*] remaining in the Term). Except as provided in this Section 1.2,
Forecasts shall be nonbinding and used and relied upon by Supplier only for Supplier’s internal capacity planning purposes. 

  

	 	1.3	 Purchase Orders. All purchases shall be pursuant to purchase orders submitted by SI-BONE to Supplier (an “Order”), which shall specify a delivery date no less than [*] after submission of the Order. SI-BONE shall submit Orders for
the number of Products. If Supplier cannot satisfy such order, then Supplier shall provide written notice to SI-BONE no later than [*] after receipt of the Order specifying its alternative delivery date which
may not be more than [*] after submission of the Order, unless otherwise agreed by the parties, provided that the Order quantities required are reasonably consistent with the current Forecast. An Order shall specify the Products ordered (including
part numbers and revision levels if applicable), quantities of each Product ordered, price, requested delivery date and requested Product recipient, all of which shall be subject to Article 5. Orders may be changed only by the mutual written
agreement of the parties. 

  

	 	1.4	 Vendors and Subcontractors. Supplier shall not (i) change the vendors from whom
Supplier sources components of the Products as of the Effective Date or (ii) subcontract its obligations to manufacture Products to subcontractors in each case without the prior written consent of SI-BONE; 

  
 Page 1 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
provided, that SI-BONE hereby acknowledges its consent to Supplier’s purchase of Product components from vendors identified in Exhibit B
(“Approved Vendors”) and use of subcontractors identified in Exhibit C (“Approved Subcontractors”). SI-BONE may order through Supplier components
sourced from Supplier’s approved vendors (which vendors may include affiliates of SI-BONE) and Supplier agrees to provide those components to SI-BONE at
Supplier’s cost [*]. Subject to the requirements of Section 4.7 of this Agreement, SI-BONE may request or otherwise require Supplier to approve and utilize alternative sources including the Approved
Vendors and Approved Subcontractors. 

  

	2.	 PRICING AND PAYMENT TERMS. 

 

	 	2.1	 During the Term, Supplier’s sales price to SI-BONE for each
Product unit shall be based on the forecasted estimated annual unit (“EAU”) volumes of Product to be purchased by SI-BONE during the Term in accordance with the pricing described in
Exhibit A (the “Pricing Addendum”). From time to time, the parties may mutually agree to add additional Products to this Agreement. 

 

	 	2.2	 The pricing set forth in Exhibit A shall be firm for the Initial Term, as defined on the
Pricing Addendum, unless the volumes vary from the forecasted EAU volume by more than [*] in either direction during the initial twelve months or during subsequent twelve month periods during the Term. In this case the Supplier or SI-BONE may request a price review based on the volume changes and the parties shall negotiate in good faith any price changes, with reference to changes in input costs and variance from EAU forecast, prior to
implementation provided that there will not be more than [*]. If the parties are unable to agree on the change in pricing through a process of good faith negotiation, then either of the parties may terminate this Agreement provided that, if the
Supplier terminates the Agreement, SI-BONE will have the option of making Last Purchase per Section 9.5. Exhibit A will be amended to reflect any mutually agreed changes to the pricing
and/or EUA volumes. Supplier may also re-price the items listed in Exhibit A in accordance with Section 6 if there are any changes made by SI-BONE to
the Specifications or materials which affect the unit costs. 

  

	 	2.3	 Supplier will invoice SI-BONE for all quantities of Products
delivered in accordance with this Agreement. Payment terms shall include a [*] discount to the Agreement price if paid within [*], and otherwise net cash [*], paid in US dollars from the date of SI-BONE’s
receipt of Supplier’s invoice. 

  

	3.	 CAPACITY. 

Supplier shall maintain capacity adequate to fulfill the Product requirements of
SI-BONE as specified in the most recent [*] rolling Forecast. Supplier hereby agrees to give timely notice to SI-BONE of any event that would reasonably be expected to
adversely affect Supplier’s capacity. Without limiting Article 1, Supplier shall use commercially reasonable efforts to assure that adequate capacity is available to fulfill future Product requirements of
SI-BONE (as determined by SI-BONE’s then-current Forecast, historical purchasing patterns and written communications to Supplier regarding anticipated
requirements). Supplier shall obtain and maintain all equipment and resources required to fulfill its obligations under this Agreement at Supplier’s sole cost, unless such equipment or resources were purchased by Supplier exclusively to supply SI-BONE. 
  

	4.	 SPECIFICATIONS; QUALITY CONTROL MATTERS. 

 

	 	4.1	 Compliance with Laws. The parties shall comply with all applicable federal, state and
local statutes, regulations, rules, ordinances and policies that pertain to the activities for which Supplier and SI-BONE are responsible under this Agreement, including those enforced by the FDA. With respect
to the Products, SI-BONE shall be the “finished device manufacturer” (as such term is used by the FDA). 

  
 Page 2 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	4.2	 Specifications. SI-BONE shall define the
specifications for the product to be manufactured by Supplier, by way of drawings, reference to commercial specifications and standards (the “Specifications”), which shall be set forth on the applicable Pricing Addendum or
Order and updated from time to time in accordance herewith. References to the initial Specifications for Product to be purchased hereunder are set forth on Exhibit E hereto and shall have been delivered to Supplier by or promptly
following the Effective Date of this Agreement. The Specifications may be paper documents, electronic documents or other appropriate media. Supplier shall deliver the Product in full conformance to the Specifications. The parties may change the
Specifications from time to time by mutual written agreement. A Product that does not conform with the Specifications and applicable laws at the time it is delivered to SI-BONE is referred to in this Agreement
as a “Nonconforming Product,” and such Product shall be regarded as having a “Nonconformity.” SI-BONE may amend or modify the Specifications from time to time in
accordance with Section 6 and shall give prompt written notice of such change(s) to the Supplier provided that Supplier will have the right to reasonably adjust the Product price to the extent that the changes made by SI-BONE affect the material, manufacturing or quality costs. 

  

	 	4.3	 Implementation of Quality Control and Risk Management Program. At all times during the
Term, Supplier shall comply with SI-BONE’s vendor qualification requirements (“Qualification Requirements”), a copy of which has been provided to Supplier. In addition, Supplier
shall maintain and comply with a quality control program that conforms with all applicable laws and is consistent with current good manufacturing practices applicable to Products (“GMPs”) and as effective during the remainder
of the Term and as required by any governmental or quasi-governmental agency having regulatory authority over the Products, including, without limitation, 21 CFR Part 820, the current released versions of ISO 13485 and 14971 (collectively, the
“Quality Management System”). In addition, Supplier shall maintain a risk management system which is integrated into its Quality Management System (the “RMS”). Supplier shall notify SI-BONE of revisions to its manufacturing procedures to the extent necessary to remain in compliance with the Qualification Requirements, GMPs or RMS, as applicable, in accordance with this Section 4.3;
provided, however, that Supplier may not make any changes to its manufacturing procedures that are inconsistent with the Specifications without the prior written consent of SI-BONE. Upon SI-BONE’s request, Supplier will provide a copy of such quality agreement(s).

  

	 	4.4	 Notification of Nonconformity. Supplier agrees to promptly notify SI-BONE in writing after Supplier obtains knowledge of its delivery to SI-BONE of any Nonconforming Product. In addition to the foregoing, Supplier shall notify SI-BONE within (a) [*] of learning of any situation which may require a recall of Products and (b) [*] of obtaining knowledge of any failure of any batch of Products to meet the standards set forth in this
Section 4.4. 

  

	 	4.5	 Acceptance; Remedy for Nonconforming Products. All Products are subject to SI-BONE’s inspection prior to acceptance. SI-BONE shall have [*] from delivery to reject Nonconforming Products. Upon detection of any Nonconformity, SI-BONE shall give written notice (which may be given by e-mail) to Supplier specifying the nature and type of alleged Nonconformity and Supplier will evaluate the alleged
Nonconformity including samples of the Nonconforming Product if requested by the Supplier. Upon agreement between the parties that the Product is Nonconforming to the Specification, Supplier shall replace such Product free of charge, and Supplier
shall cover expenses including freight, if any, in connection with (a) shipment of replacement Product to the same location and (b) shipment of the Nonconforming Product back to Supplier (if so requested by Supplier). In the absence of
such agreement between the parties or if the Supplier is unable to 

  
 Page 3 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
replace properly rejected Nonconforming Products within [*], SI-BONE may request a credit, or if payment has been made reimbursement for, the
Nonconforming Product and may, at its discretion, discontinue the purchase of the Product from Supplier and terminate this Agreement. 

  

	 	4.6	 Latent Nonconformities. Within the Warranty Period defined in 4.11, latent Nonconformities
and Nonconformities not discovered by SI-BONE pursuant to Section 4.4 through the use of reasonable inspection methods and procedures will be reported to the Supplier by
SI-BONE within [*] following detection of any Nonconformity specifying the nature and type of alleged Nonconformity. Supplier will evaluate the alleged Nonconformity including samples of the Nonconforming
Product if requested by the Supplier. Upon agreement between the parties that the Product is Nonconforming to the Specification, Supplier will replace such Product free of charge, and Supplier shall cover expenses including freight, if any, in
connection with (a) shipment of replacement Product to the same location and (b) shipment of the Nonconforming Product back to Supplier (if so requested by Supplier). In the absence of such agreement between the parties or if the Supplier
is unable to replace properly rejected Nonconforming Products within [*], Supplier shall issue a credit if payment has already been made for the Nonconforming Product, and SI-BONE may, at its discretion,
discontinue the purchase of the Product from Supplier and terminate this Agreement. 

  

	 	4.7	 Qualification of Approved Vendors and Approved Subcontractors. When requested to do so by SI-BONE, or otherwise required to do so by this Agreement, Supplier shall utilize its Purchasing Control/Vendor Qualification processes and procedures in effect at the time, to qualify third party suppliers and/or
third party manufacturers to manufacture and provide components, parts or sub-assemblies for the Product, or to manufacture and supply the Product to SI-BONE. Supplier
may, but is not necessarily required to, qualify the Approved Vendors and Approved Subcontractors. 

  

	 	4.8	 Audits. SI-BONE shall have the right, but not the
obligation, at its expense, to audit, or have audited, Supplier’s facilities, and plants that are used to manufacture and store the Products. Such audits will be conducted during Supplier’s normal business hours by SI-BONE or its designee. Supplier shall issue a plan to determine the correction, cause, and corrective action for any negative finding of any audit report issued by SI-BONE
within [*] of such audit report’s issue date. Supplier shall facilitate SI-BONE, or its authorized representative, to perform audits of any third-party supplier’s facilities, systems, documentation,
and other requirements related to this Agreement at mutually agreed dates and times. Supplier, SI-BONE, any outside auditor, and such third-party supplier shall agree on reasonable methods to protect
intellectual property, such as non-disclosure agreement or the like. 

  

	 	4.9	 Inspections. Supplier shall promptly notify
SI-BONE of any inspections, audits, formal visits, etc. of any regulator, notified body, or certification body acting in a formal capacity that are related directly to the Product. In the US this includes the
Food and Drug Administration. Supplier shall promptly notify SI-BONE of any inspection or audit findings that impact the safety, effectiveness, conformity, or availability of Product Supplier provides to SI-BONE. Supplier agrees that SI-BONE’s notified body may conduct unannounced audits of Supplier in accordance with Annex III of the 24 September 2013 Commission
Recommendations, on the audits and assessments performed by notified bodies in the field of medical devices (2013/473/EU), provided that SI-BONE will be responsible for any out-of-pocket costs incurred by Supplier and associated with third party audits performed on SI-BONE’s behalf. 

 

	 	4.10	 Insurance. During the term and for [*] after termination for any reason, the Supplier
shall maintain commercial general and product liability insurance adequate to cover any liability (including any alleged manufacturing defect or breach of warranty in Section 4.11) arising in connection with any Product manufactured by or on
behalf of Supplier and supplied to SI-BONE 

  
 Page 4 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
under this Agreement in coverage amounts consistent with normal business practices of prudent companies similarly situated. The insurance coverage shall in no event be less than [*] per loss and
[*] in the aggregate. Supplier shall provide SI-BONE with written evidence of such insurance upon request. Supplier shall provide SI-BONE with written notice at least
[*] prior to the cancellation, nonrenewal or material change in such insurance which materially adversely affects the scope or amount of such insurance coverage. 

  

	 	4.11	 Warranty. Supplier represents and warrants that all Products will conform to the
Specifications and will be free from defects in manufacture, workmanship and materials for a period of [*] (“Warranty Period”) from the date of delivery. Except as otherwise specifically provided in this Section 4 and
Section 11, whatever the basis for the claim, Suppliers obligations under this warranty are limited solely to the repair or replacement of Non-conforming Products. THIS WARRANTY IS IN LIEU OF ALL OTHER
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES REGARDING MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, RELATING TO THE USE OR PERFORMANCE OF THE PARTS. No other express or implied warranty or guaranty shall bind Supplier.
Supplier shall not be liable for its failure to conform with any requirements not adequately identified by SI-BONE in the specifications, or for personal injury or property damage, loss of revenue or profit,
failure to realize savings or other benefits, expenditures for substitute goods or services, storage charges or other special, incidental or consequential damages caused by the use, misuse or inability to use the goods, regardless of the legal
theory on which the claim is based and even if Supplier has been advised of the possibility of such damages. Without limiting the foregoing, SI-BONE assumes all risk and liability for loss, damage or injury to
persons and property of SI-BONE or others arising out of use, misuse, or inability to use any goods sold by Supplier not caused directly by the willful acts or omissions of Supplier. This warranty shall not
extend to anyone other than the SI-BONE and states SI-BONE’s exclusive remedy. The foregoing sentence shall not be interpreted to limit Supplier’s
indemnification obligations set forth in Section 11 below. All claims under this warranty must be made within the Warranty Period. 

  

	 	4.12	 Process Improvements. As required by 21 CFR Part 820 Sec. 820.50, Supplier shall not make
significant changes to the Specifications, manufacturing process, tooling design, processing conditions, materials or manufacturing location of the Products without SI-BONE’s prior written consent.
Notwithstanding the foregoing, SI-BONE will consider in good faith reasonable written requests by Supplier to change the materials or manufacturing process of the Products, provided SI-BONE shall make final determination on such change(s) in its sole discretion. 

  

	 	4.13	 Complaint Handling and Adverse Event Reporting. Each party shall cooperate fully with the
other party in dealing with customer complaints concerning the Product(s) and shall take such action to promptly resolve such complaints as may be reasonably requested by the other party. SI-BONE is
responsible for complying with all FDA and applicable foreign regulatory requirements pertaining to the receipt, review, evaluation, and where applicable, investigation of all complaints received pertaining to the Products, and for the reporting of
adverse device events, including FDA’s Medical Device Reporting requirements, codified at 21 C.F.R Part 803. Supplier shall reasonably cooperate with SI-BONE to enable
SI-BONE to fulfill such requirements. Supplier shall promptly, but in no event more than [*] after receipt of such information, provide complaint information regarding the Products to SI-BONE. 

  

	5.	 PACKAGING; LABELING; DELIVERY. 

 

	 	5.1	 Packaging and Labeling. Supplier shall be responsible for labeling and packaging Product
for shipment to SI-BONE or to its designee(s), in accordance with applicable laws, SI-BONE requirements and instructions and the additional specifications included in
the Specifications, which labeling shall include “Manufactured for SI-BONE.” SI-BONE may request changes to the packaging and labeling requirements and
Specifications upon reasonable prior written notice to 

  
 Page 5 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
Supplier. To the extent that Supplier provides input on the Product labeling or Specifications, it is understood by the parties that such activity is not intended to make Supplier a
“Specifications developer” or a “finished device manufacturer” as such terms are used by FDA. Supplier is responsible for release of product labeling, provided, however, that in the case of initial release of any new label or
labeling change, Supplier shall obtain SI-BONE’s consent to such release. SI-BONE is responsible for compliance with applicable FDA product labeling requirements.

  

	 	5.2	 Delivery. Supplier shall deliver Products by, and no more than [*] prior to, SI-BONE’s requested dates of delivery indicated in the Order or as agreed between the Supplier and SI-BONE as indicated on the Supplier Order acknowledgement. Requested
delivery dates may be changed only by mutual written agreement of the parties, which agreement shall not be unreasonably withheld or delayed. In the event that Supplier has reason to believe that it will be unable to meet the agreed upon delivery
dates, Supplier will notify SI-BONE promptly and state the reasons for the anticipated delay. All shipments of Products pursuant to this Agreement shall be shipped by Supplier FOB Supplier’s facility.
Delivery shall be deemed to have occurred, and therefore risk of loss transferred from Supplier to SI-BONE, when Products are delivered to the freight forwarder. 

 

	 	5.3	 Packing. Products shall be packed at Supplier’s sole cost and expense in accordance
with SI-BONE’s reasonable written instructions and reasonable commercial practices. Each shipment of Product shall be clearly marked as per SI-BONE’s
instructions. 

  

	6.	 PRODUCT IMPROVEMENTS. 

 

	 	6.1	 General. In the event that SI-BONE notifies
Supplier that it desires to have Supplier incorporate changes or improvements to a Product to (a) address a Product defect, integrity, safety or quality concern or compliance matter (each a “Required Improvement”) or
(b) incorporate a feature enhancement or other improvement that is a not a Required Improvement (each an “Optional Improvement,” and together with the Required Improvements, an “Improvement”), the
parties shall promptly discuss in good faith the feasibility of implementing such Improvement. 

  

	 	6.2	 Implementation of Required Improvements. Immediately following receipt of such a request
from SI-BONE regarding a Required Improvement, Supplier shall use best efforts to implement the Required Improvement as soon as possible at SI-BONE’s sole cost and
shall provide reports regarding Supplier’s implementation progress to SI-BONE upon SI-BONE’s request. All such improvements shall be evaluated and implemented
in accordance SI-BONE’s applicable design control processes and procedures that are in effect at the time that the improvements are made. SI-BONE shall update the
Design History File and Device Master Record, as applicable, and provide copies of such documentation to SI-BONE upon implementation of the Required Improvement. To the extent that Supplier provides input on
Required Improvements and changes to the Specifications, it is understood by the parties that such activity does not intend to make Supplier a “Specifications Developer” or a “finished device manufacturer” as such terms are used
by FDA. Supplier will have the right to reasonably adjust the Product price to the extent that the changes requested by SI-BONE affect the material, manufacturing or quality costs. In the event that any
Required Improvements result in a change in costs to Supplier, the parties shall negotiate in good faith a pricing change commensurate with the change in costs. If the parties are unable to agree on the change in pricing, then either of the parties
may terminate this Agreement provided that, if the Supplier terminates the Agreement, SI-BONE will have the option of making Last Purchase per Section 9.5. 

 

	 	6.3	 Implementation of Optional Improvements. In evaluating and implementing Optional
Improvements, Supplier shall use commercially reasonable efforts to minimize SI-BONE’s cost of implementing the Optional Improvements. Supplier shall provide
SI-BONE with a detailed analysis (together with supporting documentation) of the estimated costs (if any) and effect on the supply 

  
 Page 6 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
price for the applicable Product (if any) of implementing such Optional Improvement. Supplier shall implement such Optional Improvement only with
SI-BONE’s prior written consent. If Supplier notifies SI-BONE that implementation of an Optional Improvement will require any modification to the pricing set forth
on the Pricing Addendum or in the applicable Order and SI-BONE agrees, the parties will negotiate in good faith an appropriate modification to the pricing in an amendment to this Agreement. If the parties are
unable to agree on the change in pricing, then Supplier may delay implementation of the Optional Improvement until a reasonable price change is agreed; provided, however, that if the parties are unable to agree on such reasonable change in pricing, SI-BONE will have the option of terminating this Agreement provided that this termination will not relieve SI-BONE of its obligations with respect to any open Orders or
outstanding payments. All such improvements shall be evaluated and implemented in accordance with SI-BONE’s applicable design control processes and procedures that are in effect at the time that the
improvements are made. Supplier shall update the Design History File and Device Master Record, as applicable, and provide copies of such documentation to SI-BONE upon implementation of the Optional
Improvement. To the extent that Supplier provides input on Optional Improvements and changes to the Specifications, it is understood by the parties that such activity does not intend to make Supplier a “Specifications Developer” or a
“finished device manufacturer” as such terms are used by FDA. 

  

	 	6.4	 Regulatory Determination. SI-BONE shall be
responsible for making the final decision as to whether a proposed design or manufacturing change may be implemented for the Product(s). Supplier is not permitted to make any modification that affects the Product(s) without notifying SI-BONE. SI-BONE shall be responsible for making the final determination as to whether such changes require regulatory approval or clearance prior to implementation and shall
be responsible for filing and obtaining any required approvals and/or clearances, as necessary. 

  

	 	6.5	 Registration and Listing. Supplier shall comply with applicable establishment registration
requirements of the US FDA applicable to the Products and the manufacture of the Products. 

  

	7.	 INTELLECTUAL PROPERTY. 

 

	 	7.1	 Limited License. SI-BONE hereby grants Supplier a non-exclusive, nontransferable, worldwide license, without the right to sublicense, to use all designs, materials, information, know-how and documentation, including the
Specifications, provided by SI-BONE to Supplier, solely in connection with manufacturing the Products hereunder for supply of such Products to SI-BONE or parties
designated by SI-BONE. This license shall not include the right to modify, make derivative works of or improvements to the Products and shall terminate upon the termination or expiration of this Agreement. For
purposes of this Agreement, “Intellectual Property” means any inventions, improvements, developments, or innovations (including all rights to patents, copyrights, trademarks, and trade secrets and know-how inherent therein and appurtenant thereto) and other creative works (whether or not patentable or copyrightable, conceived or made or reduced to practice), know-how,
technical information, pending patent applications, registrations, divisions and continuations thereof, registered and unregistered copyrights, and all associated goodwill, designs, drawings, specifications, vendor lists, manufacturing methods and
processes, and all other information pertinent to this Agreement, which is proprietary to SI-BONE. SI-BONE’s Intellectual Property as of the date hereof includes,
but is not limited to the list set forth on Exhibit D. 

  

	 	7.2	 Ownership of Intellectual Property. All Intellectual Property of SI-BONE existing on or prior to the execution of this Agreement shall be and remain the property of SI-BONE, and Supplier shall not acquire any rights therein, except as
expressly provided in Section 7.1 of this Agreement.

  

	 	7.3	 Inventions. All Intellectual Property conceived or reduced to practice by Supplier, its
employees or agents in the course of performing Supplier’s duties hereunder and related to the Products, or as a result of access to SI-BONE’s Intellectual Property, shall be owned solely by SI-BONE and Supplier 

  
 Page 7 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
agrees to irrevocably assign all of its interests in such Intellectual Property to SI-BONE. Supplier shall execute all papers, including patent
applications, invention assignments and copyright assignments, and otherwise shall assist SI-BONE as reasonably required to perfect in SI-BONE the rights, title and
other interests held by SI-BONE under this Agreement. SI-BONE shall pay for reasonable costs related to such assistance. If
SI-BONE is unable for any reason, after reasonable effort, to secure Supplier’s signature on any document needed in connection with the actions specified above, Supplier hereby irrevocably designates and
appoints SI-BONE and its duly authorized officers and agents as its agent and attorney in fact, which appointment is coupled with an interest, to act for and in its behalf to execute, verify and file any such
documents and to do all other lawfully permitted acts to further the purposes of the preceding paragraph with the same legal force and effect as if executed by Supplier. 

 

	 	7.4	 Trade Names. Each of SI-BONE and Supplier hereby
acknowledges and agrees that it does not have, and shall not acquire, any interest in the other party’s trademarks except as expressly provided herein. Any violation of this Section 7 shall constitute a material breach of this Agreement.

  

	8.	 NON-INTERFERENCE. 

During the Term of this Agreement and for a period of [*] thereafter (the “Restricted Period”), neither
party shall, directly or indirectly, solicit for hiring, hire or accept any services or work from the other party’s employees or consultants. This restriction shall not apply to employees responding to commercially reasonable employment
advertisements in common national or regional recruiting media. The parties further agree that during the Restricted Period, the parties shall not in any way discourage any of the other party’s clients, customers or distributors or prospective
clients, customers or distributors from purchasing products, or solicit or influence or attempt to solicit or influence any client, customer, distributor or other person, either directly or indirectly, to direct any purchase of products to any other
entity in competition with the business of the other party. 
  

	9.	 TERM; TERMINATION. 

 

	 	9.1	 Term; Renewal. Unless earlier terminated in accordance with this Section 9, the term
of this Agreement shall commence on the Effective Date and continue for an initial term of three years (the “Initial Term”). This Agreement shall automatically renew for successive one year periods
(each, a “Renewal Term” and collectively, together with Initial Term, the “Term”) unless terminated by either party with [*] written notice prior to the beginning of such Renewal
Term.

  

	 	9.2	 Material Breach. Either party may terminate this Agreement in the event the other party
commits a material breach of this Agreement and has not cured such breach within [*] of written notice thereof from the non-breaching party. 

 

	 	9.3	 Termination by SI-BONE. SI-BONE may terminate this Agreement upon written notice to Supplier: 

  

	 	a.	 if Supplier fails to deliver a shipment of conforming Products in the quantities and within [*] of the mutually
agreed delivery date for a SI-BONE Order submitted in accordance with this Agreement and such failure results in a delay or Product backorder of an aggregate total (together with any other delays during the
same Supply Period) of more than [*] (a “Supply Failure”); 

  

	 	b.	 if Supplier changes the site of manufacture of any Products to a site that has not been previously approved by SI-BONE in writing; 

  

	 	c.	 in the event of a Change in Control of Supplier or Supplier sells all or substantially all of its assets
relating to the manufacturing of the Products; or 

  
 Page 8 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	d.	 if Supplier breaches Section 8 hereof (Non-Interference Covenant).

  

	 	9.4	 Insolvency. Either party may terminate this Agreement if the other party files, or has
filed against it, a petition for voluntary or involuntary bankruptcy or pursuant to any other insolvency law, or the other party makes or seeks to make a general assignment for the benefit of its creditors or applies for or consents to the
appointment of a trustee, receiver or custodian for it or a substantial part of its property, and, in the case of an involuntary bankruptcy, such situation is not cured within [*] from its occurrence, such termination to take effect upon delivery of
notice of termination to the other party. 

  

	 	9.5	 Last Purchase. If this agreement is terminated by
SI-BONE in accordance with 9.3, SI-BONE will have the option of placing a last purchase with the Supplier equal to the amount of the demand for up to a [*] period based
on the then current forecast and unit prices, to be delivered by the Supplier within a mutually agreed upon time frame or a maximum of [*]. 

  

	 	9.6	 Effect of Termination. Immediately upon expiration or termination of this Agreement,
Supplier will discontinue manufacturing the Products and the license under Section 7.1 shall terminate; provided, that expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior of such expiration
or termination. Upon termination or expiration of this Agreement, SI-BONE shall take delivery of and pay for all Products under any Order outstanding as of the date of termination only in the event of a
termination by SI-BONE under Section 9.1 unless SI-BONE terminated the Agreement for cause, and Supplier will (i) fulfill all Orders submitted to Supplier
prior to the effective date of termination and (ii) promptly return all SI-BONE documentation and property in Supplier’s possession. 

 

	 	9.7	 Survival. All of the representations, warranties, and indemnifications made in this
Agreement, and all terms and provisions hereof intended to be observed and performed by the parties after the termination hereof, including Sections 4.1, 4.3, 4.4, 4.5, 4.6, 4.8, 4.9, 4.10, 4.11, 4.13, 7.2, 7.3, 7.4, 8, 9, 10, 11 and 12 shall
survive such termination and continue thereafter in full force and effect, subject to applicable statutes of limitations. 

  

	10.	 CONFIDENTIALITY; PUBLICITY. 

 

	 	10.1	 Confidential and Proprietary Information. SI-BONE
and the Supplier will have access to each other’s Confidential and Proprietary Information. “Confidential and Proprietary Information” means any trade secret as defined by the Uniform Trade Secrets Act (“Trade
Secret”), other information viewed by the party disclosing it (the “Disclosing Party”) as confidential and/or proprietary, and any and all information or proprietary materials (in every form and media) not
generally known in the relevant trade or industry made available by either party to the party receiving such information (in such case, the “Receiving Party”) in connection with the efforts contemplated hereunder and which
the Disclosing Party designates as confidential or may reasonably be understood as confidential, including, but not limited to (i) all Intellectual Property of either party; (ii) existing or contemplated products, services, designs,
inventions, technology, processes, technical data, engineering, techniques, methodologies and concepts and any information related thereto; and (iii) information relating to business plans, sales, consultants, employees, or marketing methods
and customer lists or requirements. The Receiving Party will maintain the information in confidence using the same standard of care it uses to maintain its own Confidential and Proprietary Information in confidence, but in any case, no less than
reasonable commercial diligence, and will not use such information for itself or others except as provided in this Agreement. Such obligation of confidentiality and non-use shall not apply to information which
(a) is known to the Receiving Party prior to the disclosure as demonstrated by documentary evidence, (b) is publicly known as of the date of the disclosure, (c) becomes publicly known after the date of disclosure through no fault of
the Receiving Party, (d) is received by the Receiving Party from a 

  
 Page 9 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
third party who has, to the Receiving Party’s knowledge, no obligation of confidentiality to the Disclosing Party, or (v) is developed independently by the Receiving Party without
reference to the Disclosing Party’s Confidential and Proprietary Information as demonstrated by documentary evidence. Such obligation of confidentiality and non-use shall survive any expiration or
termination of this Agreement for a period of [*]; provided, however, that such restrictions shall survive indefinitely, or until public disclosure of the secret occurs through no fault or breach of the other party, for any information
which is Trade Secret information of a party. The restrictions on disclosure contained in this Section 10.1 shall not apply to any information which is required to be disclosed by a valid court order or governmental law or regulation, provided
that the Receiving Party gives the Disclosing Party prompt notice of any such requirement and cooperates with the Disclosing Party, at the Disclosing Party’s expense, in attempting to limit such disclosure and obtain confidential treatment
thereof. 

  

	 	10.2	 Misuse of Confidential and Proprietary Information. Each party understands and agrees that
this provision prohibits it from rendering services to another party to the extent that such party would use, disclose, or rely upon the other party’s trade secrets in the course of rendering such services or use disclose or rely upon
Confidential and Proprietary Information in any way other than for the other party’s benefit and in the furtherance of the objectives of this Agreement. 

  

	 	10.3	 Publicity. Except as otherwise provided in this Agreement or required by Law, neither
party shall use the other’s name or refer to it directly or indirectly in an advertisement, news release or release to any professional or trade publication without written approval from such party, which approval may not be unreasonably
withheld or delayed. Neither party shall use the name of the other for advertising or promotional claims without the prior written consent of the other party. 

 

	 	10.4	 Damages Inadequate. The parties acknowledge that monetary damages may be an inadequate
remedy for any breach by a party of its obligations under this Section 10 and that the non-breaching party shall be entitled to seek injunctive relief and specific performance to enforce the breaching
party’s obligations, in addition to any other remedies the non-breaching party may be entitled to at law. 

  

	11.	 REMEDIES; INDEMNIFICATION. 

 

	 	11.1	 Remedies for Nonconforming Products. In addition to any other remedies available to SI-BONE at law, in equity or hereunder, in the event Supplier delivers Nonconforming Products to SI-BONE, SI-BONE may select, and
Supplier shall provide, one of the following remedies: (a) the refund of the purchase price of the Nonconforming Products, (b) replacement with Products that conform to the Specifications, or (c) the cost of reconditioning or
reworking any Nonconforming Products to conform in all material respects with the Specifications. 

  

	 	11.2	 Indemnification by Supplier. Supplier agrees to indemnify, defend and hold SI-BONE, its affiliates, officers, directors, agents and employees (“SI-BONE Indemnitees”) harmless from and against all actions, liabilities, damages,
claims and demands whatsoever, including, but not limited to, reasonable attorney fees and other expenses (“Claims”) that are brought or threatened against the SI-BONE Indemnitees and
related to Supplier’s or Supplier Indemnitee’s: (a) breach of this Agreement; (b) violation of applicable laws and regulations; (c) breach of representations and warranties; (d) any claim of Intellectual Property
infringement brought by third parties as a direct result of Supplier’s manufacturing processes or Supplier’s services provided hereunder, provided such infringement is not a direct result of the Specifications provided by SI-BONE; or (e) gross negligence, recklessness or willful misconduct. The duty to indemnify will not apply to the extent that any Loss arises from the gross negligence, recklessness, or willful misconduct of a SI-BONE Indemnitee or SI-BONE’s breach of this Agreement. 

  
 Page 10 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	11.3	 Indemnification by SI-BONE. SI-BONE agrees to indemnify, defend and hold Supplier, its affiliates, officers, directors, agents and employees (“Supplier Indemnitees”) harmless from and against all Claims that are brought
or threatened against the Supplier Indemnitees and related to: (a) SI-BONE’s breach of this Agreement; (b) SI-BONE’s violation of applicable laws and
regulations; (c) defects or alleged defects in the design of the Products, provided such design defects are a result of specifications or instructions provided by SI-BONE and not Supplier’s
manufacturing process; (d) infringement upon the Intellectual Property rights of third parties, provided such infringement is a direct result of the Specifications or instructions provided by SI-BONE; or (e) SI-BONE’s gross negligence, recklessness or willful misconduct. The duty to indemnify will not apply to the extent that any Claim arises from the gross negligence, recklessness, or willful misconduct
of a Supplier Indemnitee or Supplier’s breach of this Agreement. 

  

	 	11.4	 Indemnification Procedure. The party claiming indemnity (the “Indemnified
Party”) shall provide the party from whom indemnity is being sought (the “Indemnifying Party”) with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the claim for
which indemnity is being sought. The Indemnifying Party shall have the right to assume sole control over the defense of such claim and conduct the defense of the claim with counsel of its choice. The Indemnifying Party shall not settle any claim
without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. 

  

	 	11.5	 Limitations of Damages. Notwithstanding anything to the contrary contained in this
Agreement, neither party shall be liable to the other party or its Affiliates (except with respect to either party’s breach of its obligations of Article 10, or indemnification obligations of Section 11.2 or 11.3 with respect to third
party claims) for any indirect, special, incidental (including, without limitation, lost profits) or punitive damages of the other party or its Affiliates from any breach or default of a party’s obligations hereunder or the breach of any
representation or warranty made hereunder. Except with respect to either party’s breach of its obligations of Article 10, or indemnification obligations of Section 11.2 or 11.3 with respect to third party claims, the collective liability
of either party to the other under this Agreement shall be limited on an aggregate basis (not per claim or occurrence) to [*], except that with respect to damages or liabilities [*]. Upon payment(s) by the they indemnifying party to the indemnified
party Supplier and/or Supplier Indemnitees to the SI-BONE and/or SI-BONE Indemnitees, or payment(s) by SI-BONE and/or the SI-BONE Indemnitees to Supplier and/or the Supplier Indemnitees, the party having made such payments shall be relieved and discharged from any further liability to the other party and/or its Indemnitees under this
Agreement, or otherwise for contribution or to defend, indemnify, and/or hold harmless the other party and/or its Indemnitees . 

  

	12.	 MISCELLANEOUS. 

 

	 	12.1	 Assignment; Binding Effect. This Agreement shall not be assignable or otherwise
transferable by Supplier without the prior written consent of SI-BONE and shall be binding upon and inure to the benefit of the parties and their respective successors and permitted assigns. This Agreement
shall not be assignable or otherwise transferable by SI-BONE without the prior written consent of Supplier, provided that SI-BONE may assign this Agreement to any
Affiliate of SI-BONE without Supplier’s consent or in connection with a merger, acquisition or sale of the stock of, or all or substantially all of the assets of,
SI-BONE. Notwithstanding anything in this Agreement, the parties acknowledge and agree that SI-BONE may perform its obligations under this Agreement through an Affiliate
of SI-BONE. 

  

	 	12.2	 Notices. All notices, requests, claims, demands and other communications hereunder shall
be in writing and shall be deemed to have been duly given (a) when received if delivered personally, including by recognized overnight delivery service, (b) when transmitted by facsimile or electronic

  
 Page 11 of 24 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	
mail (email), with confirmation of successful transmission, provided that such delivery is followed by physical delivery, (c) upon receipt, if sent by registered or certified mail (postage
prepaid, return receipt requested) and (d) the next business day after it is sent, if sent for next-day delivery to a domestic address by overnight mail or courier, to the parties at the following
addresses: 

  

			
	If to SI-BONE, to:	 	SI-BONE, Inc.
		 	3055 Olin Ave.
		 	Suite 2200
		 	San Jose, CA 95128
		 	ATTN: CFO
		 	legal@si-bone.com
		
	If to Supplier, to:	 	rms Company
		 	8600 Evergreen Blvd.
		 	Coon Rapids, MN 55433
		 	ATTN: Director of Sales

 provided, however, that if any party shall have designated a different address by notice to the
others, then to the last address so designated. 
  

	 	12.3	 Severability. If any term, provision, covenant or restriction of this Agreement is held by
a court of competent jurisdiction or other authority to be invalid, void, unenforceable or against its regulatory policy such determination shall not affect the enforceability of any others or of the remainder of this Agreement; and in connection
with such term, provision, covenant or restriction of this Agreement which is held invalid, void, unenforceable or against regulatory policy, the parties shall negotiate in good faith with a view to the substitution therefor of a suitable and
equitable solution in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid term, provision, covenant or restriction and, absent any agreement by the parties, such court of competent jurisdiction or other
authority shall substitute therefore such term, provision, covenant or restriction as is legal, valid and enforceable but otherwise similar to the invalid term, provision, covenant or restriction. 

 

	 	12.4	 Entire Agreement. This Agreement may not be amended, supplemented or otherwise modified
except by an instrument in writing signed by SI-BONE and Supplier. This Agreement contains the entire agreement of the parties hereto with respect to its subject matter, superseding all negotiations, prior
discussions and preliminary agreements made prior to the date hereof. 

  

	 	12.5	 No Third-Party Beneficiaries. This Agreement is solely for the benefit of the parties
hereto and their respective Affiliates and no provision of this Agreement shall be deemed to confer upon any third parties (other than permitted assigns) any remedy, claim, liability, reimbursement, claim of action or other right in excess of those
existing without reference to this Agreement. 

  

	 	12.6	 Waiver. The failure of any party to enforce any condition or part of this Agreement at any
time shall not be construed as a waiver of that condition or part, nor shall it forfeit any rights to future enforcement thereof. 

  

	 	12.7	 Governing Law; Jurisdiction. This Agreement (including any claim or controversy arising
out of or relating to this Agreement) shall be governed by the law of the State of Delaware without regard to conflict of law principles that would result in the application of any Law other than the Laws of the State of Delaware. Any proceeding to
interpret or enforce this Agreement will be brought exclusively in the state and federal courts situated in the state of Delaware. 

  
 Page 12 of 24 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	12.8	 Injunctive Relief. The parties acknowledge that damages would be an inadequate remedy for
any material breach of Sections 7, 8, or 10. Accordingly, notwithstanding anything to the contrary in this Agreement, either party will have the right to obtain injunctive relief in any court of competent jurisdiction to enforce Sections 7, 8, or 10
in the event of a party’s failure to perform its obligations thereunder, as well as the right to pursue any and all other rights and remedies available at law or in equity for such a breach. The breaching party hereby expressly waives the
defense that a remedy in damages will be adequate and any requirement in an action for specific performance or injunction for the posting of a bond by the party seeking injunctive relief. 

 

	 	12.9	 Counterparts. This Agreement may be executed manually or by facsimile by the parties, in
any number of counterparts, each of which shall be considered one and the same agreement and shall become effective when a counterpart hereof shall have been signed by each of the parties and delivered to each of the other parties.

  

	 	12.10	 Construction. The language in all parts of this Agreement shall be construed, in all
cases, according to its fair meaning. The parties acknowledge that each party and its counsel have reviewed and revised this Agreement and that any rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Agreement. 

  

	 	12.11	 Other Terms and Conditions. Other terms and conditions not inconsistent with terms and
conditions in this Agreement covering Products to be supplied under this Agreement will be provided in Orders by SI-BONE and in order acknowledgments and invoices issued by Supplier. In the event of any
conflict of terms in these documents, SI-BONE and Supplier agree to negotiate in good faith to resolve such differences, unless such terms conflict with the terms of this Agreement, in which case the terms of
this Agreement shall control. 

  

	 	12.12	 Further Assurances. SI-BONE and Supplier covenant
and agree that subsequent to the execution and delivery of this Agreement and without any additional consideration, each of SI-BONE and Supplier shall execute and deliver any further legal instruments and
perform such acts which are or may become necessary to effectuate the purposes of this Agreement. 

  

	 	12.13	 Relationship. Supplier is an independent contractor engaged by SI-BONE for the provision of the Products. Nothing in this Agreement shall constitute either party as an employee, agent or general representative of the other, nor shall either
SI-BONE or Supplier have the right or authority to assume, create or incur any liability or any obligation of any kind, express or implied, against, or in the name of or on behalf of, the other.

 [REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK] 

  
 Page 13 of 24 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the parties hereto have caused this Manufacturing, Quality and
Supply Agreement to be executed by their respective duly authorized officers as of the date set forth below their names. 
  

									
	By:	 	 /s/ Laura Francis
	 		 	By:	 	 /s/ Richard Riddle

	Name:	 	Laura Francis	 		 	Name:	 	Richard Riddle
					
	Title:	 	Chief Financial Officer	 		 	Title:	 	Director of Sales
					
	Date:	 	2/1/2017	 		 	Date:	 	2/1/2017

  
 Page 14 of 24 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A 

PRICING ADDENDUM 
 [*] 

  
 Page 15 of 24 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT B 

APPROVED VENDORS 
 [*] 

  
 Page 16 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT C 

APPROVED SUBCONTRACTORS 
 [*] 

  
 Page 17 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT D 

INTELLECTUAL PROPERTY 
 [*] 

  
 Page 18 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT E 

PRODUCT SPECIFICATIONS 
  

							
	 Item
	 	 Part Number
	 	 Document Title
	 	 Document Type

	 [*]
	 	[*]	 	[*]	 	[*]

 Note: Future revision updates to be applied through mutual signed agreement of both parties through the change control
process. 

  
 Page 19 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Addendum No. 1 to 

Quality and Manufacturing Agreement by and 

between rms COMPANY and SI-BONE, Inc. 

This Addendum No. 1 to Quality and Manufacturing Agreement (“Addendum
No. 1”) is entered into between rms COMPANY (“Supplier”) and SI-BONE, Inc.
(“SI-BONE”) and modifies and supplements that certain Manufacturing, Quality and Supply Agreement by and between the parties with an effective date of January 31, 2017 (the
“Original Agreement”, and together with this Addendum No. 1, the “Agreement”). This Addendum No. 1 is intended to, among other things, allow Supplier to hold a specified level of inventory to
better support SI-BONE’s business. Capitalized terms used and not defined in this Addendum No. 1 shall have the meaning given them in the Original Agreement. 

I.    Amendment. The following provisions of the Original Agreement are amended and restated
in their entirety as set forth below: 
  

	 	a.	 Section 1.2 of the Original Agreement is hereby amended and restated as set forth below: 

“1.2 Forecasts. Within ten days after the Effective Date, SI-BONE shall
deliver to Supplier a forecast of its requirements for the Product for each of the calendar quarters ending June 30, 20XX, September 30, 20XX, December 31, 20XX, and March 31, 20XX (with the period ending March 31, 2017 including the period
starting with the Effective Date) (the “Forecast”). Such Forecast shall include requirements for Product by part number (as set forth on Schedule A to this Addendum No. 1) and by calendar month for the applicable period,
and at the elected of SI-BONE, by calendar week. No later than ten days following the end of each [*] during the Term, SI-BONE shall update the Forecast in writing by
providing to Supplier an updated Forecast for the following [*] (or such fewer number of [*] remaining in the Term). Except as provided in this Section 1.2 and this Addendum No. 1, Forecasts shall be nonbinding and used and relied upon by
Supplier only for Supplier’s internal capacity planning purposes.” 
  

	 	b.	 Section 1.3 of the Original Agreement is hereby amended and restated as set forth below:

 “1.3    Purchase Orders. SI-BONE
shall deliver to Supplier a blanket purchase order for all Product specified in each Forecast no later than [*] prior to the first anticipated delivery date of any Product under such Forecast (a “Blanket PO”) for the purpose
of Supplier’s maintenance of Inventory (as defined in Section 1.5 below). All purchases shall be pursuant to purchase orders submitted by SI-BONE to Supplier (an “Order”),
which, other than Orders made against the Blanket PO (a ‘Drawdown Order”), shall specify a delivery date no less than [*] after submission of the Order, provided that any Drawdown Order shall specify a deliver date no
less than [*] after submission of such Order. SI-BONE shall submit Orders for the number of Products. If Supplier cannot satisfy any Order that is not a Drawdown Order, then Supplier shall provide
written notice to SI- BONE no later than [*] after receipt of the Order specifying its alternative delivery date which may not be more than [*] after submission of the Order, unless otherwise
agreed by the parties, provided that the Order quantities required are reasonably consistent with the current Forecast. SI- BONE shall deliver Drawdown Orders to Supplier on a monthly basis and any Product
ordered pursuant to such Drawdown Order shall be based on the minimum release lot sizes as 

  
 Page 20 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
set forth on Schedule A to this Addendum No. 1. Any Product ordered pursuant to a Drawdown Order shall be shipped within [*] of Supplier’s receipt of such Drawdown Order. An Order shall
specify the Products ordered (including part numbers and revision levels if applicable), quantities of each Product ordered, price, requested delivery date and requested Product recipient, all of which shall be subject to Article 5. Orders may be
changed only by the mutual written agreement of the parties.” 
  

	 	c.	 The Original Agreement is hereby amended to include the following Section 1.5:

 “1.5 Inventory. Supplier shall maintain available Inventory of “machined Product” and
“finished Product”, in each case based on the then current Forecast, for delivery pursuant to Sections 1.3 and 5.2, as set forth on Schedule A to this Addendum No. 1. For purposes hereof, (i) “machined Products” shall mean
Product additively manufactured and machined but unpackaged, and (ii) “finished Products” shall mean machined additively manufactured Product, packaged and sterilized pursuant to the Agreement. The terms “machined Products” and
“finished Products” are collectively referred to here as “Inventory”. Supplier and SI-BONE agree to meet on a quarterly basis for the purpose of adding or removing Products, or adjusting
Inventory levels of the Products, listed on Schedule A. In the event Supplier maintains any “finished Product” in Inventory for more than [*], upon notice from Supplier of such event, SI-BONE shall
deliver a Drawdown Order against any such “finished Product”, provided, however, that SI-BONE shall have no obligation to purchase in excess of [*] of Inventory based on the original Forecast
delivered to Supplier. Supplier shall be solely responsible for maintaining sufficient Inventory to satisfy the delivery requirements under the Agreement and for any loss, damage or replacement to any Inventory.” 

 

	 	d.	 The second sentence of Section 4.3 of the Original Agreement is hereby amended and restated as set
forth below: 

 “Supplier shall maintain and comply with a quality control program that conforms with all applicable laws and is
consistent with current good manufacturing practices applicable to Products (“GMPs”) and as effective during the remainder of the Term and as required by any governmental or quasigovernmental agency having regulatory
authority over the Products, including, without limitation, 21 CFR Part 820, the current released versions of ISO 13485 and 14971, and shall establish and maintain procedures for identifying with a control number each unit, lot, or batch of
“finished Products” and where appropriate components of such “finished Products” (collectively, the “Quality Management System”).” 

 

	 	e.	 Section 5.2 of the Original Agreement is hereby amended and restated as set forth below:

 “5.2 Delivery. Supplier shall deliver Products by, and no more than [*] prior to, SIBONE’s requested
dates of delivery indicated in the Order or as agreed between the Supplier and SIBONE as indicated on the Supplier Order acknowledgement, provided however, Products ordered pursuant to any Drawdown Order shall be shipped within [*] of
Supplier’s receipt of such Drawdown Order. Requested delivery dates may be changed only by mutual written agreement of the parties, which agreement shall not be unreasonably withheld or delayed. In the event that Supplier has reason to believe
that it will be unable to meet the agreed upon delivery dates, Supplier will notify SI-BONE promptly and state the reasons for the anticipated delay. All shipments of Products pursuant to this Agreement shall
be shipped by Supplier FOB Supplier’s facility. Delivery shall be deemed to have occurred, and therefore risk of loss transferred from Supplier to SI-BONE, when Products are delivered to the freight
forwarder. All Product ordered pursuant to a Drawdown Order from Inventory shall be shipped in a “first in – first out” basis in order minimize the amount of time any Product is maintained by Supplier in Inventory.” 

  
 Page 21 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	 	II.	 Miscellaneous. 

 

	 	1)	 Severability. If any provision of the Original Agreement, including this Addendum No. 1, will be
declared invalid, illegal or unenforceable, such provision will be severed and all remaining provisions will continue in full force and effect. 

  

	 	2)	 Entire Agreement. The Original Agreement, including this Addendum No. 1, is the full, complete, and
exclusive agreement between the parties and supersedes and cancels any and all previous or contemporaneous agreements of whatever nature, whether written or oral, between Supplier and SI-BONE and their
respective subsidiaries and affiliates with respect to its subject matter. The Original Agreement, including this Addendum No. 1, may only be modified or amended in writing signed by both parties. Subject headings are for convenience of
reference only and will in no way affect interpretation of the Original Agreement. 

  

	 	3)	 Counterparts. This Addendum No. 1 may be executed in separate counterparts, and by facsimile, each
of which will be deemed an original, and when executed separately or together, will constitute a single original instrument, effective in the same manner as if the parties had executed one and the same instrument. 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 Page 22 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the parties have executed this Addendum No. 1 as of the date
set forth beneath such person’s name. 
  

									
	SI-BONE:	 		 	SUPPLIER:
			
	SI-BONE, Inc.	 		 	rms Company
					
	By:	 	 /s/ Laura Francis
	 		 	By:	 	 /s/ Richard S. Riddle

	Name:	 	Laura Francis	 		 	Name:	 	Richard S. Riddle
					
	Title:	 	Chief Financial Officer	 		 	Title:	 	Director of Sales
					
	Dated:	 	July 7, 2017	 		 	Dated:	 	July 6, 2017

  
 Page 23 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Schedule A to Addendum No. 1 

 

							
	 Part Number
	  	 Minimum

Release Lot

Size
	  	 Weeks Inventory

(finished

Products)
	  	 Weeks Inventory

(machined

Products)

	 [*]
	  	[*]	  	[*]	  	[*]

  
 Page 24 of
24 
 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]